The Food and Drug Administration (FDA) has questioned the kind of benefits that drugs related to lupus treatment provide. These drugs have been made by Human Genome Sciences Inc. and GlaxoSmithKline PLC and the FDA has said that the risks are far more in number than the benefits.

The medicine is known as Benlysta and as the FDA says, it, "appeared to be associated with an increase in death, serious adverse events" such as serious infections and adverse psychiatric events that included three suicides."

Benlysta is said to be one of the most important drugs in pipeline of Glaxo and if it is approved as false, then it will hit the medicine company badly. It is one of the first drugs of the company for decades.

The review of FDA on Benlysta is going to be released in the upcoming Tuesday meeting. The same will then be reviewed by medical experts and they will be coming from the arthritis advisory committee.

And the views of the panel is utmost importance when the drug will get to be approved for markets.